NEW YORK (GenomeWeb News) – UK-based contract research and synthetic DNA firm SpheriTech said today that it has received an investment of an undisclosed sum from an anonymous angel investor.

The company is using the funds, which it said is in the six-figure range, to hire additional staff and to attract other investors and win government research grants or loans.

"For a company like ours to get off the ground, it's absolutely essential to secure government finance," SpheriTech CEO and Founder Don Wellings said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.